The Quinoline Era

The "Quinoline Era" is a name used by veterans, advocates, and researchers to describe the period — beginning in the late 1980s and continuing to the present — during which quinoline-class antimalarial drugs, primarily mefloquine and tafenoquine, were administered to Australian Defence Force personnel with inadequate safety monitoring, inadequate adverse-event reporting, and, for many, lasting harm.

The word "quinoline" refers to the chemical structure shared by both drugs. Neither drug is new — mefloquine was developed in the 1970s and tafenoquine in the 1980s, both initially by the United States Army — but their full neurological risk profile took decades of accumulated evidence, regulatory intervention, and veteran testimony to come into focus.

The era is defined not just by the drugs but by a set of institutional failures that surrounded them: clinical trials conducted on active-duty personnel without adequate informed consent processes; adverse events that were systematically under-reported to regulators; a misdiagnosis pattern that left neurologically injured veterans being treated for psychological trauma they may not have had; and a compensation system that could not easily recognise the condition these veterans actually had.

The era is not closed. Veterans are still living with the consequences. Research into long-term effects remains incomplete. Institutional responses — from the Department of Veterans' Affairs, the Department of Defence, and the Royal Commission — are still evolving. What changed most significantly in 2024 was that the Royal Commission into Defence and Veteran Suicide formally acknowledged, in its final report, that this is a real issue requiring a real response.

How this page handles evidence

Evidential discipline

This page uses four categories of evidence to maintain clarity: established facts supported by primary sources; contested claims where credible experts or institutions disagree; areas of uncertainty where research is incomplete or absent; and contradictions between sources, where official positions diverge. This helps readers understand what is known, what is debated, and what has not yet been studied.

Between 1998 and 2002, the Australian Army Malaria Institute ran a series of clinical trials of mefloquine and the then-unregistered drug tafenoquine, using ADF personnel deployed on active operations as trial participants. These trials are at the heart of what is now called the Quinoline Era.

The Army Malaria Institute

The Army Malaria Institute (AMI) was the ADF's dedicated research unit for tropical infectious diseases, based at Gallipoli Barracks in Enoggera, Queensland. Its mission was to develop and test preventatives and treatments for the malaria and other tropical diseases that threatened ADF operations in the region. The AMI was funded by the Australian Government but also received funding from the United States Army Medical Materiel Development Activity (USAMMDA) and, for the tafenoquine trials, from GlaxoSmithKline.

This combination — military-run trials, pharmaceutical funding, and service personnel as subjects — created a conflict of interest that advocates, researchers, and ultimately the 2018 Senate inquiry identified as a significant factor in what went wrong. Medical officers within the military structure had professional obligations both to their patients and to the trial program.

The Bougainville trials (1998–1999)

The first major tafenoquine trial used ADF personnel deployed to Bougainville (PNG) as part of peacekeeping operations. Approximately 378 personnel received tafenoquine and 214 received primaquine (the then-standard post-exposure treatment) as a comparator. These were some of the earliest Phase II/III trials of tafenoquine in a military deployment setting.

The East Timor trials (1999–2002)

The East Timor trials were larger and more consequential. Three separate trial protocols were run across this period:

• Trial 2 (1999–2000): 636 personnel received tafenoquine as post-exposure prophylaxis; 289 received primaquine.
• Trial 3 (2000–2001, "the Nasveld trial"): 492 personnel received tafenoquine as prophylaxis; 162 received mefloquine as comparator. This study found vortex keratopathy in 93.2% of tafenoquine recipients assessed ophthalmologically. It also found that neuropsychiatric adverse events were reported in 13.4% of tafenoquine recipients and 11.7% of mefloquine recipients. No neuropsychiatric adverse events from this trial were reported to the TGA at the time.
• Trial 4 (2001–2002, "the Kitchener trial"): 1,157 personnel received mefloquine and 388 received doxycycline. This trial found that 57% of mefloquine users reported at least one adverse event, including sleep disturbance in 31% and fatigue in 21%. Three serious neuropsychiatric adverse events were recorded as possibly related to mefloquine. The headline conclusion — that 94% of participants said they would take mefloquine again — was widely cited as evidence of tolerability, despite the significant adverse-event figures in the same paper.

What the inquiry found about the trials

The 2018 Senate inquiry identified a number of serious concerns about the way these trials were conducted:

• Adverse events were significantly under-reported to the TGA, both during and after the trials. The vortex keratopathy finding is the clearest example: 93.2% occurrence in the trial, but only five adverse-event reports lodged with the TGA, all categorised as "visual impairment."
• The informed-consent process did not adequately disclose the neuropsychiatric risk profile of the drugs, particularly for tafenoquine, which was unregistered at the time.
• No longitudinal follow-up of trial participants was ever conducted. Veterans who developed symptoms after the trials had no record in their health files connecting their condition to their participation.
• The publication of safety data was delayed and the framing of adverse-event rates in published papers diverged from the raw data in ways that created a misleadingly positive safety narrative for mefloquine in military settings.

ADF policy: then and now

Mefloquine entered the ADF antimalarial inventory as a second-line agent in 1990. It remained in relatively wide use through the 1990s and early 2000s, including as a trial comparator in East Timor. In 2006, the ADF demoted mefloquine to third-line status, meaning atovaquone/proguanil (Malarone) became the preferred alternative when doxycycline was contraindicated. Mefloquine should now only be prescribed when both first- and second-line alternatives are unavailable.

Tafenoquine received TGA registration in 2018. The Senate inquiry recommended that any future administration of tafenoquine in the ADF be subject to careful medical oversight. The Royal Commission in 2024 went further in recommending a specific brain-injury program for those exposed to mefloquine or tafenoquine.

Understanding what the trials produced leads directly to the scientific question: what do these drugs do in the brain, and why do some effects persist long after exposure ends.

There is now a substantial body of peer-reviewed evidence that mefloquine and tafenoquine can cause serious, lasting neuropsychiatric effects in a proportion of people who take them. What remains contested is the precise mechanism, the prevalence of lasting injury, and whether that injury constitutes a clinically distinct condition separate from other neuropsychiatric disorders.

What is well established

The neuropsychiatric adverse effects of mefloquine are documented across more than three decades of pharmacovigilance data, clinical trial reports, and case series. The US FDA's 2013 boxed warning is the most significant regulatory statement: it acknowledged that neurological side effects — including dizziness, balance problems, tinnitus, and neuropsychiatric symptoms including anxiety, paranoia, depression, hallucinations, and psychosis — can persist for months to years after the drug is stopped, or can be permanent.

The European Medicines Agency reached a similar conclusion in 2014, finding evidence of long-lasting and potentially persistent neuropsychiatric and vestibular effects.

A 2015 study by Ringqvist and colleagues in Denmark followed 73 people who had reported mefloquine adverse reactions. They found that years after stopping the drug, significant proportions continued to experience anxiety (55%), recurring nightmares (59%), cognitive dysfunction (59%), and paranoia or delusions (51%). These figures come from a population that had already reported adverse reactions — they are not prevalence rates across all mefloquine users — but they provide the most detailed published picture of what long-term mefloquine injury can look like.

Research by US physician and epidemiologist Dr Remington Nevin — the most prolific single contributor to this literature — has used regulatory adverse-event data, case series, and pharmacological analysis to build a framework for what he calls "neuropsychiatric quinism," a condition he argues is caused by direct pharmacological injury to the brainstem, limbic system, and vestibular system. Nevin's work has been published in peer-reviewed journals and cited in Australian parliamentary submissions.

What remains contested

The concept of "chronic quinoline encephalopathy" or "neuropsychiatric quinism" as a discrete, formally recognised clinical entity is still contested. The Australian Repatriation Medical Authority (RMA) investigated this question in 2017 and concluded that there was insufficient sound medical-scientific evidence to establish a causal link between quinoline exposure and a distinct form of acquired brain injury. The Specialist Medical Review Council confirmed this finding in 2018.

Other researchers have argued that the evidence for lasting harm is weaker than advocates contend, noting that many studies rely on self-reported symptoms, small samples, and populations with a prior adverse-event history (which creates selection bias). A large US study published in 2017 (Eick-Cost et al.), examining neuropsychiatric outcomes in nearly 370,000 service members, found that mefloquine was associated with increased PTSD diagnoses in non-deployed personnel — a finding consistent with neurotoxic effects — but did not find broad neuropsychiatric harm across all outcome categories.

The pharmacogenomics question

There is a growing body of evidence suggesting that genetic variation in liver enzymes — particularly CYP2D6 and CYP3A4/5, which are involved in metabolising these drugs — may help explain why some people develop severe adverse reactions and others do not. Jane Quinn, scientific adviser to the Quinoline Veterans and Families Association, found that 92% of ADF veterans with documented long-term adverse effects who provided genetic data were identified as poor or intermediate metabolisers at one or both of these enzyme loci. No pharmacogenomic screening was performed for trial participants at the time.

This is a plausible and clinically important area, but it has not been studied systematically in the ADF cohort. Routine pharmacogenomic profiling before administering these drugs was recommended by the QVFA and by the Quinn Senate submission, but has not been implemented.

What we still do not know

The most significant gap in the evidence base is the absence of any systematic, longitudinal follow-up study of ADF trial participants. No study has tracked the health of the roughly 1,500 personnel who received tafenoquine in the AMI trials over the decades since. The University of Queensland study commissioned by Defence and DVA in 2018 used existing 2007–2008 survey data and was explicitly limited by small numbers of mefloquine users, a cross-sectional design, and recall bias. It found some association between mefloquine use and poorer health outcomes in Bougainville veterans, but could not draw causal conclusions.

There is no established treatment specifically for quinoline-induced neurological injury. There are no validated diagnostic protocols for distinguishing it from PTSD in someone who has also had combat exposure. And the potential intergenerational effects on the children of affected veterans have not been studied at all.

These scientific uncertainties shaped how symptoms were interpreted — and in many cases misinterpreted — when veterans returned from deployment.

Veterans returning from East Timor and Bougainville with persistent neuropsychiatric symptoms — rage, paranoia, nightmares, cognitive impairment, emotional numbing — entered a clinical system that had, at the time, essentially one framework for understanding those symptoms in returned soldiers: post-traumatic stress disorder.

PTSD is a real, serious, and well-documented condition. The clinicians who diagnosed it were not acting in bad faith. They were applying the framework they had been trained to apply. The problem is that the symptom profile of quinoline-induced neuropsychiatric injury overlaps with PTSD so closely that, without specific training in quinoline neurotoxicity, differential diagnosis is extremely difficult.

Why the symptoms look the same

Why PTSD became the default

Several factors converged to make PTSD the near-universal diagnosis for these veterans:

• No clinical training in quinoline neurotoxicity. The FDA's boxed warning did not exist until 2013. The forensic psychiatric literature identifying a mefloquine intoxication syndrome as a distinct clinical entity was not published until around the same time. Clinicians assessing veterans in the early 2000s had no diagnostic framework for what they were seeing.
• Institutional architecture built around PTSD. DVA and ADF health services were oriented toward identifying and treating service-related psychological conditions. PTSD was the predominant category. There was no referral pathway to acquired brain injury specialists, and no entitlements pathway for quinoline-induced neurological injury.
• The deployment narrative. Combat experience is a powerful and culturally available explanation for veteran distress. In the clinical encounter, what happened on deployment provides a coherent story that supports a PTSD diagnosis. The drug history was not part of that conversation — it was not collected, not flagged, and not considered relevant.
• No systematic screening. No follow-up health assessment of AMI trial subjects was ever conducted. Veterans with symptoms had no record in their files connecting them to their trial participation.
• The entitlements structure. The DVA's Statements of Principles provided a compensation pathway for veterans diagnosed with PTSD but not for those correctly diagnosed with quinoline-induced acquired brain injury — a condition the RMA had not recognised. A correct diagnosis offered no entitlements pathway; an incorrect one did.

Why this matters for treatment

PTSD and quinoline-induced neurological injury are fundamentally different kinds of condition with different mechanisms and different treatment implications. PTSD is a psychological response to traumatic experience; it responds to trauma-focused psychotherapy and appropriate pharmacotherapy. Quinoline-induced injury is a direct pharmacological effect on brain tissue — in the most precise clinical sense, an acquired brain injury — and it does not respond to treatments designed for PTSD.

For a veteran with quinoline-induced injury being treated for PTSD, the result was years of treatment that did not address the actual injury. Some advocates and researchers have argued that trauma-focused therapy — which repeatedly activates threat-related emotional content — may in some cases amplify rather than reduce symptoms in a person whose limbic system has been pharmacologically injured. This is a clinical inference consistent with the difference in injury mechanisms; it has not been formally studied in this population.

The two conditions can also co-occur. A veteran may have genuine PTSD from combat exposure and quinoline-induced neurological injury from the drug they were given on the same deployment. Getting the diagnosis right does not mean dismissing the combat experience — it means addressing both.

For a deeper account of what quinoline injury does to the brain, and how it differs mechanistically from PTSD, see The Brain. These misdiagnoses had profound consequences not only for veterans but for everyone living with them.

For many veterans, the effects of mefloquine or tafenoquine did not end when the deployment did. Some symptoms began during the deployment. Others emerged weeks or months after returning. In some cases, symptoms that seemed manageable in the short term intensified over years. This pattern — of symptoms that persist, fluctuate, and in some cases worsen — is what the published case literature and advocacy record consistently describe.

Prodromal symptoms: the early warning signs

The current Australian product information for mefloquine advises that if common symptoms of an adverse reaction occur — changes in mood, anxiety, or altered dream or sleep states — the drug must be discontinued. These "prodromal" symptoms are now understood as potential early warnings of more serious and lasting toxicity. For many veterans in the AMI trials, and many ADF members prescribed mefloquine for deployment, these warnings were either not recognised, not acted upon, or not reported.

The spectrum of long-term effects

Based on the published clinical literature, the Ringqvist (2015) case series, the FDA adverse-event database, and the testimony of veterans to the Senate inquiry and Royal Commission, the range of long-term effects reported by those who attribute them to quinoline exposure includes:

• Persistent anxiety, depression, and emotional dysregulation
• Recurring nightmares and severe sleep disturbances, sometimes for years
• Cognitive difficulties: impaired memory, concentration, and executive function
• Vestibular dysfunction: dizziness, balance problems, tinnitus, and vertigo
• Visual disturbances, including light sensitivity (photophobia)
• Paranoid ideation and, in some cases, psychotic episodes
• Personality changes described by veterans and their families as fundamental shifts in who the person was before deployment
• Suicidal ideation and, in some documented cases, completed suicide

It is important to be clear about the evidential status of this list. That these symptoms have been reported is a documented fact. That quinoline exposure caused them — rather than combat stress, other medication, or pre-existing conditions — is in some cases firmly established by the clinical timeline and in others contested. The RMA found insufficient evidence to establish a general causal link between quinoline exposure and lasting brain injury. The Royal Commission took a different view.

Vestibular dysfunction: the distinguishing feature

Among the reported long-term effects, vestibular dysfunction — chronic dizziness, balance difficulties, and spatial disorientation — has particular diagnostic significance. These symptoms are not typical features of PTSD, and their presence alongside neuropsychiatric symptoms in someone with confirmed quinoline exposure may help distinguish quinoline injury from other conditions. Nevin (2015) has noted that subtle neurosensory damage, including vestibular effects, in the absence of a severe initiating traumatic incident, can aid in differential diagnosis.

Suicide

The FDA boxed warning for mefloquine explicitly includes suicidal ideation and completed suicide in the list of reported adverse events. Cases of suicide among veterans who took mefloquine are documented in the TGA's adverse-event database and in testimony to the Royal Commission. Establishing direct causation in individual cases is methodologically difficult, but the Royal Commission's Chapter 22 engagement with this population reflects a judgment that the relationship between these drugs and veteran suicide is real and serious.

If you are having thoughts of suicide, please contact Open Arms on 1800 011 046 (available 24 hours) or Lifeline on 13 11 14.

Is recovery possible?

The honest answer is: we do not know enough. The FDA's 2013 label states that effects can be permanent, but it also notes that many adverse effects are time-limited or improve after discontinuation of the drug. The published case literature includes people who recovered substantially and people whose symptoms persisted for many years. There is no established disease-specific treatment. There are no clinical trials of treatment approaches specific to this cohort.

What the Quinoline Veterans and Families Association and the Senate inquiry both emphasised is that correct diagnosis is the necessary first step — because treatment calibrated to the wrong condition will not help, and may in some cases make things worse.

For more on the neurological mechanisms behind these symptoms, see The Brain. For what this injury looked like inside a home, see The Household.

The effects of quinoline-induced neurological injury did not stay with the veteran. They moved into households, into relationships, and into the childhoods of people who had nothing to do with the ADF. Partners and children have described living with consequences that were never correctly named, never correctly explained, and never appropriately supported.

What partners experienced

Partners and spouses of affected veterans describe living alongside someone who changed — sometimes gradually, sometimes suddenly — after returning from deployment. The changes they describe include explosive rage that could come without warning, paranoid suspicion that extended to family members, deep emotional withdrawal, and an inability to be present in the relationship even when physically in the room.

For years, these partners were told — by clinicians, by the veterans' affairs system, by the narrative that surrounded PTSD — that what they were seeing was the consequence of what their veteran had witnessed in a combat environment. The treatment being offered to their veteran was treatment for that. Partners were enrolled in support frameworks designed for families of people with PTSD, not frameworks designed for households where someone has an acquired brain injury affecting impulse control, paranoia, and emotional regulation.

The safety implications are real. Rage episodes and paranoid ideation in a household are not abstract clinical concerns. For some partners, the experience was one of living with a person whose most dangerous symptoms were being treated with an approach that did not reach them.

What children experienced

Children who grew up in households affected by quinoline injury were growing up in circumstances that no adult around them could accurately explain. The cycling between rage and remorse, the paranoid accusation, the emotional inaccessibility of a parent — these were the presentation of an unaddressed neurological injury. For many of these children, there was no clinical framework available to the adults in their lives that could name what was happening or design support around it.

The long-term effects on children raised in these households have not been systematically studied. Advocates have raised the question of intergenerational impacts, but this remains an area where there is essentially no research.

The support gap

The 2018 Senate inquiry included support for partners, carers, and families of affected veterans in its terms of reference. Written submissions described families who sought help and found that support was either unavailable or contingent on the veteran's condition being first recognised by DVA — which, for many years, it was not. The Royal Commission similarly heard from family members in private sessions.

The support system that exists for military families — principally Open Arms — provides counselling for family members of veterans, but it was designed around psychological conditions, not neurological ones. The specific needs of families living with quinoline-induced acquired brain injury are not met by that framework as currently designed.

For accounts specific to partners, see The Spouse. For the experience of children raised in these households, see The Children. For the household as a whole, see The Household. These lived experiences eventually reached formal inquiries — with mixed results.

The history of official responses to the quinoline issue in Australia is, in part, a history of incomplete recognition followed by gradual movement. The key formal findings are documented below. The gap between what advocates have called for and what institutions have delivered remains significant.

In February 2017, the RMA opened a formal investigation into whether "chemically-acquired brain injury caused by mefloquine, tafenoquine, or primaquine" should become a recognisable condition under the veterans' entitlements framework. The investigation was prompted by advocacy from the QVFA and others.

In August 2017, the RMA concluded that there was insufficient sound medical-scientific evidence to make a Statement of Principles for this condition. This was a significant finding for veterans seeking compensation, because without an SOP, claims for this specific condition have no clear pathway through the DVA system.

The RMA did not find that the drugs were harmless. It continued to recognise mefloquine and tafenoquine as causal factors in a range of other conditions covered by existing SOPs — including anxiety disorder, depressive disorder, bipolar disorder, tinnitus, sensorineural hearing loss, peripheral neuropathy, epileptic seizure, and suicide. The core contradiction is that the drugs are accepted as causes of many separate conditions but not of an integrated brain-injury syndrome.

The QVFA and the Quinism Foundation (US) challenged the RMA's decision at the Specialist Medical Review Council, an independent review body. The SMRC confirmed the RMA's decision on 18 September 2018, finding that the evidence base did not support departing from the RMA's conclusion.

The Foreign Affairs, Defence and Trade References Committee conducted a Senate inquiry into mefloquine and tafenoquine use in the ADF, tabling its report on 4 December 2018. The committee heard from veterans, families, advocates, researchers, the Department of Defence, and international experts.

The committee accepted that veterans' symptoms were genuine. Its "weight of evidence" conclusion was that long-term problems from mefloquine are rare and that the evidence for long-term effects from tafenoquine was not compelling — a conclusion contested by advocates and some researchers. It did not recommend an apology, a DVA Gold Card, or a royal commission (all of which the QVFA had called for).

The 14 recommendations fell into four broad areas: research-ethics reform, claims and support, clinical guidelines, and a neurocognitive health program. The Government agreed to 12 recommendations and agreed in principle to 2 others in its response of 15 March 2019.

The Bupa program: what happened next

The Government committed $2.1 million to a national GP health-assessment program for affected veterans, announced on 15 March 2019 and implemented from 1 July 2019. The contract was awarded to Bupa without a public tender process. By the time the program ran, only 109 assessments were provided — far below the number of veterans affected. The contract was subsequently referred to the National Anti-Corruption Commission. This outcome is widely regarded by advocates as emblematic of the gap between formal policy commitments and their actual delivery.

Royal Commission into Defence and Veteran Suicide (2024)

The Royal Commission into Defence and Veteran Suicide was the most significant official engagement with this issue to date. Its Final Report, delivered on 9 September 2024, devoted Chapter 22 of Volume 4 to mefloquine and tafenoquine. Expert testimony from Dr Jane Quinn was included in the Commission's deliberations.

Recommendation 61 called for the establishment of a brain-injury program covering, at a minimum: relevant Army corps, Special Forces, Navy clearance divers, Air Force combat controllers, and serving and ex-serving members who were exposed to mefloquine and/or tafenoquine. This was the first time an Australian body at the Royal Commission level had accepted the framework of brain injury — rather than psychiatric disorder — as the appropriate lens for this population.

The government's response to the Royal Commission's recommendations, including Recommendation 61, was still being developed at the time this page was last updated. The Quinoline Era remains an open chapter of Australian military history.

What the Quinoline Veterans and Families Association has called for

The QVFA, as the primary advocacy organisation for affected veterans and families, has consistently called for a broader set of responses than any official body has delivered. These include: a formal apology from the ADF; DVA Gold Cards for all veterans exposed to quinoline antimalarials during their service; a Royal Commission specifically into the use of ADF members in clinical trials; a single Statement of Principles for quinoline poisoning covering the full syndrome rather than its individual symptoms; CYP450 pharmacogenomic profiling for all ADF members; a ban on using ADF veterans as subjects in clinical trials; and a longitudinal research program including investigation of potential intergenerational effects on veterans' children.

These are advocacy positions, not official findings. They are documented here because they represent what the affected community has said it needs, and because the gap between these positions and what has been formally delivered is part of the record.

Australia's experience sits within a wider international pattern — other militaries encountered the same drugs, the same problems, and in some cases moved to address them sooner.

Australia was not alone in using mefloquine extensively in military populations — and not alone in the problems that followed. The experiences of the United States, the United Kingdom, and Canada offer important context, both because they show that this was a systemic issue across multiple military organisations and because the regulatory and policy responses in other countries often moved faster than Australia's.

United States

The US military was mefloquine's original developer and its most extensive user. The FDA added its boxed warning in July 2013, making explicit that neurological effects could be permanent. Following the warning, then-Assistant Secretary of Defense Jonathan Woodson directed that mefloquine be used only if four other antimalarial drugs had failed. US Army Special Operations Command effectively prohibited it. By 2015, US military prescriptions had fallen from a 2003 peak of roughly 50,000 to around 216 per year.

Mefloquine's use by US Special Forces in 2002 and subsequent events at Fort Bragg — which involved a cluster of domestic homicides and suicides among soldiers who had recently returned from Afghanistan — brought intense public scrutiny. Whether mefloquine was a factor in those events was contested by military authorities and was never officially established, but the episode accelerated advocacy for reform.

United Kingdom

A 2014 study by a Royal Navy medical officer found that 54% of naval personnel taking mefloquine on deployment reported at least one adverse event, with 13% experiencing events serious enough to require withdrawal from treatment. All female personnel in the study reported at least one adverse event.

The UK House of Commons Defence Committee reported in May 2016, recommending that mefloquine be a drug of last resort, given only after individual risk assessment and when no alternative is available. The Ministry of Defence revised its policy in September 2016.

Canada

Between 2001 and 2012, approximately 16,000 Canadian soldiers deployed to Afghanistan received mefloquine. Following advocacy by affected veterans and media coverage, the Canadian Armed Forces Surgeon General commissioned an independent task force, which reported in 2017. Canada subsequently adopted a more cautious prescribing framework.

European Medicines Agency

In 2014, the EMA's Pharmacovigilance Risk Assessment Committee found a signal of long-lasting and potentially persistent neuropsychiatric and vestibular effects from mefloquine, leading to updated labelling across Europe. This finding preceded the Australian Senate inquiry by four years.

Understanding this history helps explain both the timeline of recognition and the support pathways that now exist for Australian veterans and their families.

If you are a veteran who took mefloquine or tafenoquine on deployment — or a family member of someone who did — there are support pathways available. Some are not yet adequate to the problem; that gap is part of what this page documents. But there are people and services who can help.

Making a DVA claim

Veterans seeking to make a DVA claim for conditions related to quinoline antimalarial exposure face a complex landscape. Because there is no single Statement of Principles for quinoline poisoning, claims must generally be made under the relevant SOPs for individual conditions — such as anxiety disorder, depressive disorder, tinnitus, or sleep disorder — and mefloquine or tafenoquine must be shown to be a causal factor in the relevant condition under that SOP.

The Senate inquiry recommended that a simpler claims pathway be established. As of the last update to this page, the Royal Commission's Recommendation 61 (a brain-injury program) may represent the most significant step toward a more coherent pathway — but implementation depends on the government's response.

Engaging a veteran advocate through the QVFA, ADSO, or an ex-service organisation is advisable before lodging a complex claim. Open Arms can also assist with navigation.

Non-liability health care

Veterans who were part of the mefloquine or tafenoquine clinical trials may be entitled to DVA non-liability health care while a claim is being assessed. This was one of the Senate inquiry's recommendations. Contact DVA on 1800 633 567 to discuss your eligibility.

The sources and further reading below set out the primary documents, peer-reviewed literature, and advocacy submissions on which this page is based.

This page draws on primary sources wherever possible. The label next to each source indicates its type: Official/Primary government, regulatory, or parliamentary documents; Peer-reviewed scientific and medical literature; Advocacy submissions and reports from veteran organisations; Media investigative journalism and public reporting.